

Recombinant Human B-Cell Maturation Antigen/TNFRSF17 (Human BCMA/TNFRSF17)

Product Information

Product Name	Cat#	Size
Recombinant Human B-Cell Maturation Antigen/TNFRSF17 (Human BCMA/TNFRSF17)	90607ES08	5 µg
	90607ES60	100 µg
	90607ES76	500 µg

Product Description

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF receptor superfamily. It is a type III membrane protein containing one extracellular cysteine rich domain. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. TNFRSF17 can binds to TNFSF13B/BLYS/BAFF and TNFSF13/APRIL, and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

Product Properties

Synonyms	TNFRSF17, BCM, CD269
Accession	Q02223
GeneID	608
Source	E.coli-derived Human BCMA/TNFRSF17, Ala5-Ala54.
Molecular Weight	Approximately 5.4 kDa.
AA Sequence	AGQCSQNEYF DSSLHACIPC QLRCSNTPP LTCQRYCNAS VTNSVKGTNA
Tag	None
Physical Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.
Purity	> 98% by SDS-PAGE and HPLC analyses.
Biological Activity	The ED ₅₀ as determined by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated murine B cells is no less than 40 ng/mL, corresponding to a specific activity of > 2.5 × 10 ⁴ IU/mg in the presence of 100 ng/mL human APRIL. Fully biologically active when compared to standard.
Endotoxin	< 1.0 EU per 1µg of the protein by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered concentrated solution in 30 % acetonitrile, 0.1% TFA. We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom.
Reconstitution	Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.

Shipping and Storage

The products are shipped with ice pack and can be stored at -20°C to -80°C for 1 year.

Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

Cautions

1. Avoid repeated freeze-thaw cycles.
2. For your safety and health, please wear lab coats and disposable gloves for operation.
3. For research use only.